The influence of androgen deprivation therapy on metabolism in patients with prostate cancer

Journal of Clinical Endocrinology and Metabolism

Volumn 90, Issue 2, 2005, Pages 657-660

  Nishiyama, Tsutomu ^a   Ishizaki, Fumio ^a   Anraku, Tsutomu ^a   Shimura, Hisanobu ^a   Takahashi, Kota ^a  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; ANTIANDROGEN; CALCIUM; CHOLESTEROL; DEOXYPYRIDINOLINE; FLUTAMIDE; GLUCOSE; GONADORELIN AGONIST; HEMOGLOBIN; PHOSPHORUS; URIC ACID;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ARTICLE; BODY WEIGHT; BONE DENSITY; CANCER HORMONE THERAPY; CANCER INHIBITION; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COGNITIVE DEFECT; DEPRESSION; DUAL ENERGY X RAY ABSORPTIOMETRY; ERYTHROCYTE COUNT; GLUCOSE BLOOD LEVEL; GYNECOMASTIA; HEMATOCRIT; HEMOGLOBIN DETERMINATION; HUMAN; MALE; METABOLISM; MUSCLE ATROPHY; OSTEOPOROSIS; PRIORITY JOURNAL; PROSTATE CANCER; RADIUS; SEXUAL DYSFUNCTION; SIDE EFFECT; UREA NITROGEN BLOOD LEVEL; URIC ACID BLOOD LEVEL; VASOMOTOR DISORDER;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; BLOOD GLUCOSE; BLOOD UREA NITROGEN; BODY WEIGHT; CHOLESTEROL; DENSITOMETRY, X-RAY; ERYTHROCYTE COUNT; FLUTAMIDE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; ORCHIECTOMY; PROSTATIC NEOPLASMS;

EID: 14044269583     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2004-1611     Document Type: Article

References (26)

1. Huggins C, Hodges CV 1941 Studies on prostate cancer. Effect of castration, estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1:293-297
2. Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Gil T, Collette L, Pierart M 1997 Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 337:295-300
3. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D 1999 Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 341:1781-1788
4. Morley JE 2003 Testosterone and behavior. Clin Geriatr Med 19:605-616
5. Vermeiden A 2002 Ageing, hormones, body composition, metabolic effects. World J Urol 20:23-27
6. Thompson CA, Shanafelt TD, Loprinzi CL 2003 Andropause: symptom management for prostate cancer patients treated with hormonal ablation. Oncologist 8:474-487
7. Medlinsky JT, Napier CD, Gurney CW 1969 The use of an antiandrogen to further investigate the erythropoietic effects of androgens. J Lab Clin Med 74:85-92
8. McLeod DG, Vogelzang NJ 2000 Androgen blockade: monotherapy and quality-of-life issues. In: Vogelzang NJ, Scardino PT, Shipley WU, Coffey DS, eds. Comprehensive textbook of genitourinary oncology, 2nd Ed. Philadelphia: Lippincott Williams & Wilkins; 824-834
9. Nishiyama T, Kanazawa S, Watanabe R, Terunuma M, Takahashi K 2004 The influence of hot flashes on quality of life in patients with prostate cancer treated with androgen deprivation therapy. Int J Urol 11:735-741
10. Nishiyama T, Hashimoto Y, Takahashi K 2004 The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer. Clin Cancer Res 10:7121-7126
11. Weber JP, Walsh PC, Peters CA, Spivak JL 1991 Effect of reversible androgen deprivation on hemoglobin and serum immunoreactive erythropoietin in men. Am J Hematol 36:190-194
12. Strum SB, McDermed JE, Scholz MC, Johnson H, Tisman G 1997 Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. Br J Urol 79:933-941
13. Diamond TH, Higano CS, Smith MR, Guise TA, Singer FR 2004 Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies. Cancer 100:892-899
14. Japan Osteoporosis Society 2002 Guideline for correct usage of markers of bone metabolism for osteoporosis. Osteop Jpn 10:251-261
15. Miyaji Y, Saika T, Yamamoto Y, Kusaka N, Arata R, Ebara S, Nasu Y, Tsushima T, Kumon H 2004 Effects of gonadotropin-releasing hormone agonists on bone metabolism markers and bone mineral density in patients with prostate cancer. Urology 64:128-131
16. Arrer E, Jungwirth A, Mack D, Frick J, Patsch W 1996 Treatment of prostate cancer with gonadotropin-releasing hormone analogue: effect on lipoprotein[a]. J Clin Endocrinol Metab 81:2508-2511
17. Smith MR, Finkelstein JS, McGovern FJ, Zietman AL, Fallon MA, Schoenfeld DA, Kantoff PW 2002 Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 87:599-603
18. Smith JC, Bennett S, Evans LM, Kynaston HG, Parmar M, Mason MD, Cockcroft JR, Scanlon MF, Davies JS 2001 The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab 86:4261-4267
19. Darlington LG, Ainsworth JG, Blight A, Khong MD, Mann TA, Waldon RD, Warburton EA 1991 Changes in urate metabolism after castration of patients suffering from carcinoma of the prostate. Adv Exp Med Biol 309A:235-238
20. Dockery F, Bulpitt CJ, Agarwal S, Rajkumar C 2002 Testosterone suppression in men with prostate cancer is associated with increased arterial stiffness. Aging Male 5:216-222
21. Dockery F, Bulpitt CJ, Agarwal S, Donaldson M, Rajkumar C 2003 Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clin Sci (Lond) 104:195-201
22. Zamboni PF, Simone M, Passaro A, Doh Dalla Nora E, Fellin R, Solini A 2003 Metabolic profile in patients with benign prostate hyperplasia or prostate cancer and normal glucose tolerance. Horm Metab Res 35:296-300
23. Higano CS 2004 Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician. Urol Clin North Am 31:331-352
24. Rashid MH, Chaudhary UB 2004 Intermittent androgen deprivation therapy for prostate cancer. Oncologist 9:295-301
25. Smith MR, Goode M, Zietman AL, McGovern FJ, Lee H, Finkelstein JS 2004 Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. J Clin Oncol 22:2546-2553
26. Tay MH, Kaufman DS, Regan MM, Leibowitz SB, George DJ, Febbo PG, Manola J, Smith MR, Kaplan ID, Kantoff PW, Oh WK 2004 Finasteride and bicalutamide as primary hormonal therapy in patients with advanced adenocarcinoma of the prostate. Ann Oncol 15:974-978